Farmakoterapie po infarktu myokardu

Jiří Vítovec, Jindřich Špinar

Cor Vasa 2009, 51(2)  

The usual dosage regimen of statins and adherence to target LDL-cholesterol levels by Czech patients in the secondary prevention of coronary heart disease

Otto Mayer jr., Jaroslav Šimon, Jan Bruthans, Markéta Galovcová, Jana Hrbková, Jiří Bělohoubek

Cor Vasa 2009, 51(2):92-96 | DOI: 10.33678/cor.2009.025  

Background: Statins are a critical component of pharmacotherapy in the secondary prevention of coronary heart disease (CHD). It is evident from new-generation statin trials that aggressive lipid-lowering may further increase the benefit of CHD patients.Aims: To determine the usual dosage regimen of statins and whether target values of LDL-cholesterol (LDL) are achieved in patients with manifest CHD.Design of study: A descriptive, pragmatic survey of a systematically selected sample (EUROASPIRE III).Methods: 600 consecutive patients, men and women aged ≤ 80 years, were identified retrospectively with the following diagnoses: coronary...

Heart-rate slowing drugs in the treatment of myocardial infarction survivors

Jiří Vítovec, Jindřich Špinar

Cor Vasa 2009, 51(2):97-102 | DOI: 10.33678/cor.2009.026  

The authors present a review of heart rate-slowing drugs given to myocardial infarction survivors, including digoxin as an inotrope, beta-blockers reducing sympathetic activity, calcium-channel blockers such as verapamil, diltiazem with their vasodilator action, and the sinus node inhibitor ivabradine, which is currently undergoing clinical trials. The article discusses current concepts and lists indications for their use in secondary prevention in patients after myocardial infarction.

ACE inhibitors or sartans in the management of myocardial infarction survivors?

Jindřich Špinar, Jiří Vítovec

Cor Vasa 2009, 51(2):103-111 | DOI: 10.33678/cor.2009.027  

This paper is a review of current concepts regarding renin-angiotensin-aldosterone system blockade after myocardial infarction. The established classes of drugs such as ACE inhibitors, angiotensin II receptor blockers, or aldosterone inhibitors as well as novel direct renin inhibitors are discussed. While data from trials in hypertensive patients have suggested some benefit of ACE inhibitors, head-to-head comparisons in large multicenter trials have supported the notion that ACE inhibitors and angiotensin receptor blockers are effective, safe and comparable, yet their combinations do not seem appropriate. Aldosterone inhibitors are added in some indications,...

Antithrombotic therapy after acute myocardial infarction

Ota Hlinomaz

Cor Vasa 2009, 51(2):112-117 | DOI: 10.33678/cor.2009.028  

Antithrombotics are basic agents for the prevention and treatment of acute coronary syndromes. They are divided into antiplatelet and anticoagulant agents. The most important oral agents are acetylosalicylic acid, clopidogrel and warfarin. Novel antithrombotics such as prasugrel, ticagrelor, rivaroxaban and dabigatran seem to be promising. The vast majority of patients after acute myocardial infarction should be treated with aspirin plus clopidogrel for 12 months unless there is an excessive risk of bleeding or a contraindication.

Treatment of dyslipidemia after myocardial infarction

Vladimír Soška

Cor Vasa 2009, 51(2):119-122 | DOI: 10.33678/cor.2009.029  

Lipid-lowering drugs, and statins in particular, are the mainstay of treatment in myocardial infarction survivors. Statins are indicated in post-MI patients whose LDL-cholesterol levels are above the target; treatment should be initiated already during hospitalization. Fibrates are indicated in the combination with statins in patients with low HDL-cholesterol levels and/or increased triglyceride levels persisting while on statins. Lipid-lowering therapy should be always combined with non-pharmacological treatment, i.e., lifestyle modifications. Every effort should be made to reach target LDL-cholesterol levels as well as optimal triglyceride and HDL-cholesterol...

Preventive cardiology 1995-2005. Its achievements and disappointments (EUROASPIRE I, II, III)

Jaroslav Šimon, Hana Rosolová, Otto Mayer jr.

Cor Vasa 2009, 51(2):123-127 | DOI: 10.33678/cor.2009.030  

The ultimate goal of treatment of patients with coronary heart disease (CHD) is to reduce the risk of another cardiovascular event, prevent complications of the disease, extend life, and improve its quality.EUROASPIRE I (European Action on Secondary Prevention by Intervention to Reduce Events) was conducted in nine European countries in 1995-1996, with 15 European nations participating in EUROASPIRE II. Both surveys showed that the potential for secondary prevention in patients surviving a coronary event was largely underused. The two surveys were followed, in 2006-2007, by EUROASPIRE III carried out in as many as 22 European countries to map the...

Brno Registry - Drug therapy after myocardial infarction

Jindřich Špinar, Milan Sepši, Ondřej Ludka

Cor Vasa 2009, 51(2):128-130 | DOI: 10.33678/cor.2009.031  

The authors present a review of antiplatelet therapy taken by patients discharged from Brno University Hospital over the years 2005-2008. Data of a total of 2,005 cases of acute myocardial infarction occurring in 1,858 patients were analyzed; 88 patients died while hospitalized, 1,917 patients were discharged to receive home care or care in another health-care facility. Upon discharge, 89.15% of patients were on ACE inhibitors or angiotensin II receptor blockers, 89.51% on beta-blockers, 93.74% on antiplatelet agents, and 89.50% of patients were taking a lipid-lowering drug. Three in four of these patients were on all four drug classes, with another...

What are our chances to reach the new LDL-cholesterol treatment goals in secondary prevention?

Otto Mayer jr.

Cor Vasa 2009, 51(2):131-135 | DOI: 10.33678/cor.2009.032  

A number of clinical trials have shown patients with overt coronary heart disease may benefit from more aggressive lowering of LDL-cholesterol to 2 mmol/L, or even lower. The current guidelines define this concentration of LDL as the optional treatment goal. We sought to determine to what extent it is feasible to reach this new target in clinical practice and to assess the costs involved.

Doporučení pro diagnostiku a léčbu ischemické choroby dolních končetin

Miroslav Bulvas

Cor Vasa 2009, 51(2):145-163 | DOI: 10.33678/cor.2009.036  

Sharon Moalem: Zdraví zabíjí. Proč potřebujeme nemoci

Prof. MUDr. Jan Petrášek, DrSc.

Cor Vasa 2009, 51(2):168  

Subakutní uzávěr arteria axillaris, vzniklý na podkladě embolizace z tumoru plic prorůstajícího do levé síně

Tomáš Paleček, Stanislav Beran, Ondřej Šmíd, Petr Mitáš

Cor Vasa 2009, 51(2):136 | DOI: 10.33678/cor.2009.033  

Zápis ze schůze výboru ČKS, konané dne 20. listopadu 2008 v Praze

I. Kraicigerová, L. Klímová, V. Chaloupka

Cor Vasa 2009, 51(2):170  

Nový systém internetové učebny pro celoživotní vzdělávání sester

Jiří Neumann

Cor Vasa 2009, 51(2):164  

Oral urapidil in the treatment of arterial hypertension today

Josef Švejda

Cor Vasa 2009, 51(2):138-141 | DOI: 10.33678/cor.2009.034  

Urapidil is the only representative of drugs with combined action: central agonist activity at the serotonin 5 HT1A receptor, and peripheral postsynaptic antagonist activity on alpha 1-adrenoceptors. It decreases peripheral vascular resistance while inhibiting increased sympathetic tone by modulation of cardiovascular centers thereby hindering reflex tachycardia. When administered orally, urapidil induces a gradual and long-term decrease in systolic and diastolic blood pressure without a significant rise in heart rate. The incidence of orthostatic hypotension is low. In its oral controlled-release form, urapidil is indicated for the treatment of hypertension,...

Zamyšlení nad historií protektivního ovlivnění ischemického myokardu

Prof. MUDr. Bohuslav Ošťádal DrSc.

Cor Vasa 2009, 51(2):144  

Tiráž a obsah

Cor Vasa 2009, 51(2):85-87, 89  

Deset "NEJ" v KARDIOLOGII 2008

Cor Vasa 2009, 51(2):165-167  

Kalendář odborných akcí

Cor Vasa 2009, 51(2):171-172